2020
Utility of spontaneous animal models of Alzheimer’s disease in preclinical efficacy studies
Zeiss CJ. Utility of spontaneous animal models of Alzheimer’s disease in preclinical efficacy studies. Cell And Tissue Research 2020, 380: 273-286. PMID: 32337614, DOI: 10.1007/s00441-020-03198-6.Peer-Reviewed Original ResearchConceptsHuman Alzheimer's diseaseSpontaneous animal modelAlzheimer's diseaseAnimal modelsBiomarker progressionProgression of neuropathologyLate-onset Alzheimer's diseasePreclinical efficacy studiesHuman clinical trialsOnset Alzheimer's diseaseUsable outcome measuresAD-associated mutationsFamilial Alzheimer's diseaseNon-human primatesAmyloid neuropathologyInterventional studyClinical trialsSpontaneous modelHuman trialsOutcome measuresTherapeutic successPotential therapyNew therapiesRodent studiesEfficacy studies
2017
From Reproducibility to Translation in Neurodegenerative Disease.
Zeiss CJ. From Reproducibility to Translation in Neurodegenerative Disease. ILAR Journal 2017, 58: 106-114. PMID: 28444192, DOI: 10.1093/ilar/ilx006.Peer-Reviewed Original ResearchConceptsNeurodegenerative diseasesPreclinical studiesDisease-altering treatmentsComplex human neurodegenerative diseasesBody of evidenceAnimal study designHuman neurodegenerative diseasesOutcome measuresTherapeutic studiesPreclinical successPharmacologic criteriaTherapeutic potentialStudy designDiseaseIndividual diseasesAnimal experimentsBiomarker dataTranslational purposesCell-based systemsConcept studyStudy design methodsPredictive validityPhenotypic variabilityPatientsStudyEstablished patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease
Zeiss CJ, Allore HG, Beck AP. Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease. PLOS ONE 2017, 12: e0171790. PMID: 28182759, PMCID: PMC5300282, DOI: 10.1371/journal.pone.0171790.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesClinical outcome measuresDisease-modifying interventionsNon-human primatesParkinson's diseaseOutcome measuresStudy designHuman studiesToxin-induced modelsHuman interventional studiesLongitudinal clinical outcomesPreclinical study designStudy design dataToxic protocolsClinical outcomesContemporary cohortNeuropathologic dataStudy design factorsInterventional studyMultiple time pointsPD phenotypeAnimal studiesIntervention characteristicsIntervention categoriesProgressive nature